We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $977M
1-Year Est. Return 110.37%
This Fund
S&P 500
This Quarter Est. Return
-3.4%
1 Year Est. Return
+110.37%
3 Year Est. Return
+306.38%
5 Year Est. Return
+741.86%
10 Year Est. Return
–
AUM
$970M
AUM Growth
-$80.8M
Cap. Flow
+$19.9M
Cap. Flow %
2.05%
Top 10 Hldgs %
34.67%
Holding
117
New
17
Increased
44
Reduced
27
Closed
27

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$35.1M
2
PTCT icon
PTC Therapeutics
PTCT
+$19.2M
3
NVST icon
Envista
NVST
+$18.5M
4
SYK icon
Stryker
SYK
+$17.7M
5
ABBV icon
AbbVie
ABBV
+$16.6M

Top Sells

Rank Stock Value
1
MASI
Masimo
MASI
+$26M
2
TERN
Terns Pharmaceuticals
TERN
+$25.1M
3
FOLD
Amicus Therapeutics
FOLD
+$21.2M
4
MCK icon
McKesson
MCK
+$21.1M
5
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$18M

Sector Composition

Rank Sector Weight
1 Healthcare 99.48%
2 Miscellaneous 0.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSP icon
101
Inspire Medical Systems
INSP
$1.78B
– –
-15,000
Closed -$1.38M
MASI
102
DELISTED
Masimo
MASI
– –
-200,000
Closed -$26M
MNKD icon
103
MannKind Corp
MNKD
$1.27B
– –
-640,356
Closed -$3.63M
MTD icon
104
Mettler-Toledo International
MTD
$28B
– –
-10,988
Closed -$15.3M
PGEN icon
105
Precigen
PGEN
$2.49B
– –
-1,002,826
Closed -$4.19M
PTGX icon
106
Protagonist Therapeutics
PTGX
$9.34B
– –
-25,973
Closed -$2.27M
RPID icon
107
Rapid Micro Biosystems
RPID
$78.8M
– –
-354,465
Closed -$1.03M
SDGR icon
108
Schrodinger
SDGR
$1.47B
– –
-298,939
Closed -$5.35M
SENS icon
109
Senseonics Holdings Inc
SENS
$493M
– –
-206,793
Closed -$1.14M
SYRE icon
110
Spyre Therapeutics
SYRE
$7.97B
– –
-124,485
Closed -$4.08M
TERN
111
DELISTED
Terns Pharmaceuticals
TERN
– –
-620,877
Closed -$25.1M
TMCI icon
112
Treace Medical Concepts
TMCI
$302M
– –
-199,393
Closed -$489K
TMDX icon
113
Transmedics
TMDX
$3.07B
– –
-45,174
Closed -$5.5M
TVTX icon
114
Travere Therapeutics
TVTX
$6.19B
– –
-86,297
Closed -$3.3M
UNH icon
115
UnitedHealth
UNH
$353B
– –
-31,875
Closed -$10.5M
VERA icon
116
Vera Therapeutics
VERA
$2.46B
– –
-100,564
Closed -$5.09M
MDLN
117
Medline Inc
MDLN
$31B
– –
-20,558
Closed -$863K
1 2 3 4
5

Similar funds

KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
ACM
Arini Captial Management London, United Kingdom $975M AUM
FM
Family Management New York $975M AUM 23.16% 1-Year Est. Return
PAMI
Perseverance Asset Management International George Town, Cayman Islands $979M AUM 50.58% 1-Year Est. Return
PFGIA
Patriot Financial Group Insurance Agency Westborough, Massachusetts $974M AUM 29.77% 1-Year Est. Return
SI
Seeds Investor New York $973M AUM 33.7% 1-Year Est. Return
HIGP
Hill Investment Group Partners St. Louis, Missouri $980M AUM 22.33% 1-Year Est. Return
SCA
Stillwater Capital Advisors Devon, Pennsylvania $981M AUM 31.05% 1-Year Est. Return

Parkman Healthcare Partners's Q1 2026 Portfolio in Review

As of Q1 2026, Parkman Healthcare Partners held 117 positions worth $970M, down 7.7% from $1.05B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Parkman Healthcare Partners's Q1 2026 filing shows 17 new, 44 increased, 27 reduced and 27 closed positions. Its largest new stake was Eli Lilly: 34,616 shares worth $31.8M. The largest sale was Masimo, an estimated $26M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

  • Parkman Healthcare Partners's largest Q1 2026 buy was Eli Lilly: 34,616 shares worth $31.8M.
  • Parkman Healthcare Partners added most to PTC Therapeutics in Q1 2026, an estimated $19.2M increase.
  • Parkman Healthcare Partners's biggest Q1 2026 reduction was McKesson, cutting an estimated $21.1M.
  • Parkman Healthcare Partners fully exited Masimo in Q1 2026, selling an estimated $26M.
  • Parkman Healthcare Partners's ten largest holdings make up 35% of its $970M portfolio in Q1 2026.
  • Parkman Healthcare Partners opened 17 new positions and closed 27 in Q1 2026.
  • Parkman Healthcare Partners's portfolio value fell 7.7% quarter-over-quarter to $970M.

Based on Parkman Healthcare Partners's 13F filing for Q1 2026, filed 15 May 2026.